Aldeyra Therapeutics announced positive top-line data from a Phase 2 clinical trial comparing reproxalap ophthalmic solution 0.25% (reproxalap) versus Novartis’ Xiidra (lifitegrast ophthalmic solution 5%),…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.